EP 3867645 B1 20240605 - BIOMARKERS FOR A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY IMMUNE INDEX THAT CHARACTERIZES DISEASE ACTIVITY
Title (en)
BIOMARKERS FOR A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY IMMUNE INDEX THAT CHARACTERIZES DISEASE ACTIVITY
Title (de)
BIOMARKER FÜR KRANKHEITSAKTIVITÄTIMMUNINDEX VON SYSTEMISCHEM LUPUS ERYTHEMATODES (SLE) ZUR CHARAKTERISIERUNG DER KRANKHEITSAKTIVITÄT
Title (fr)
BIOMARQUEURS D'INDICE IMMUNITAIRE D'ACTIVITÉ DE MALADIE DU LUPUS ÉRYTHÉMATEUX DISSÉMINÉ (SLE) QUI CARACTÉRISE UNE ACTIVITÉ DE MALADIE
Publication
Application
Priority
- US 201862747455 P 20181018
- US 2019052917 W 20190925
Abstract (en)
[origin: WO2020081204A1] The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine/adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune Index (LDAII) score.
IPC 8 full level
G01N 33/564 (2006.01); G01B 5/00 (2006.01); G01N 33/68 (2006.01)
CPC (source: EP KR US)
G01N 33/564 (2013.01 - EP KR US); G01N 33/6803 (2013.01 - US); G16H 50/20 (2018.01 - EP); G16H 50/30 (2018.01 - EP); G01N 2333/52 (2013.01 - EP); G01N 2800/104 (2013.01 - EP US); G01N 2800/52 (2013.01 - EP KR); G01N 2800/56 (2013.01 - EP KR); Y02A 90/10 (2018.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2020081204 A1 20200423; AU 2019360758 A1 20210520; CA 3116539 A1 20200423; CA 3116539 C 20231003; CN 113196059 A 20210730; EP 3867645 A1 20210825; EP 3867645 A4 20220713; EP 3867645 B1 20240605; JP 2022505422 A 20220114; JP 7248788 B2 20230329; KR 102554477 B1 20230711; KR 20210102189 A 20210819; US 2021349088 A1 20211111; ZA 202102511 B 20220629
DOCDB simple family (application)
US 2019052917 W 20190925; AU 2019360758 A 20190925; CA 3116539 A 20190925; CN 201980083467 A 20190925; EP 19873181 A 20190925; JP 2021521430 A 20190925; KR 20217011372 A 20190925; US 201917286221 A 20190925; ZA 202102511 A 20210416